Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC

(IDH)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Amendment of Form 8.3 - Shareholder Value Beteiligungen AG: PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

06/10/2021 | 09:01am EDT
Shareholder Value Beteiligungen AG (IDH) 
Amendment of Form 8.3 - Shareholder Value Beteiligungen AG: PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A 
PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 
10-Jun-2021 / 14:59 CET/CEST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
FORM 8.3 
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY 
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 
Rule 8.3 of the Takeover Code (the "Code") 
 This form replaces the forms released by Shareholder Value Management AG and Shareholder Value Beteiligungen AG 
released at 16:13 and 16:35 respectively on 28 May 2021 
1. KEY INFORMATION 
 
                                                                                           Shareholder Value Management 
                                                                                           AG (SVM) 
(a) Full name of discloser: 
                                                                                           Shareholder Value 
                                                                                           Beteiligungen AG (SVB) 
(b) Owner or controller of interests and short positions disclosed, if different from 1 
(a): 
                                                                                           n.a. 
 The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), 
settlor and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:    Immunodiagnostic Systems 
                                                                                           Holding 
 Use a separate form for each offeror/offeree 
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify    n.a. 
identity of offeror/offeree: 
(e) Date position held/dealing undertaken: 
                                                                                           9/6/2021 
 For an opening position disclosure, state the latest practicable date prior to the 
disclosure 
(f) In addition to the company in 1(c) above, is the discloser making disclosures in 
respect of any other party to the offer?                                                   NO 
 If it is a cash offer or possible cash offer, state "N/A" 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 
                                                                    2p ordinary 
 
                                                                                                           Short 
                                                                    Interests                              positions 
 
                                                                    Number                   %             Number     % 
                                                                                             1,69 (SVM)+ 
                                                                    487.245 (SVM) +2.809.351 
(1) Relevant securities owned and/or controlled:                    (SVB)                    9,76 (SVB) 
                                                                    In total: 3.296.596      In total: 
                                                                                             11,45% 
(2) Cash-settled derivatives: 
 
 
(3) Stock-settled derivatives (including options) and agreements to 
purchase/sell: 
 
                                                                    3.296.596                11,45% 
 TOTAL: 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1 (c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

                           Purchase/sale 
Class of relevant security               Number of securities Price per unit 
 
 
 
 

(b) Cash-settled derivative transactions

                  Product       Nature of dealing 
Class of relevant description                                                            Number of reference  Price per 
security                        e.g. opening/closing a long/short position, increasing/  securities           unit 
                  e.g. CFD      reducing a long/short position 
 
 
 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

                                                                                   Type 
Class of      Product          Writing,            Number of securities Exercise                       Option money 
relevant      description e.g. purchasing,         to which option      price per  e.g.         Expiry paid/ received 
security      call option      selling, varying    relates              unit       American,    date   per unit 
                               etc.                                                European 
                                                                                   etc. 
 

(ii) Exercise

Class of relevant         Product description Exercising/ exercised 
security                                      against                      Number of securities Exercise price per unit 
                          e.g. call option 
 
 
 

(d) Other dealings (including subscribing for new securities)

                           Nature of dealing 
Class of relevant security                               Details Price per unit (if applicable) 
                           e.g. subscription, conversion 
 
 
 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to 
relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the 
disclosure and any party to the offer or any person acting in concert with a party to the offer: 
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or 
understandings, state "none" 
 
 none 
 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure 
and any other person relating to: 
(i) the voting rights of any relevant securities under any option; or 
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is 
referenced: 
If there are no such agreements, arrangements or understandings, state "none" 
 
 none 
 

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?  NO 
Date of disclosure:  10 June 2021 
Contact name:        Andreas Springer 
Telephone number*:   +49 / 69 66983024 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk. -----------------------------------------------------------------------------------------------------------------------

ISIN:          DE000A168205 
Category Code: RET - Immunodiagnostic Systems Holdings PLC 
TIDM:          IDH 
LEI Code:      529900V1ZBO7TDIQX144 
Sequence No.:  110640 
EQS News ID:   1206712 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1206712&application_name=news 
 

(END) Dow Jones Newswires

June 10, 2021 09:00 ET (13:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC 0.00% 378 Delayed Quote.80.00%
SHAREHOLDER VALUE BETEILIGUNGEN AG -0.78% 128 Delayed Quote.30.61%
All news about IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC
06/10AMENDMENT OF FORM 8.3 - SHAREHOLDER : Public opening position disclosure/dealin..
EQ
06/10AMENDMENT OF FORM 8.3 - SHAREHOLDER : Public opening position disclosure/dealin..
DJ
05/28IMMUNODIAGNOSTIC  : Form 8.3 Immunodiagnostic Systems Holdings PLC
EQ
05/28FORM 8.3 - SHAREHOLDER VALUE BETEILI : Immunodiagostic Systems Holdings PLC
EQ
05/28FORM 8.3 - SHAREHOLDER VALUE BETEILI : Immunodiagostic Systems Holdings PLC
DJ
05/25DIASORIN S P A  : Launches Antigen Test To Detect COVID-19 Infection
MT
05/19PERKINELMER  : Bionity - PerkinElmer to Acquire In-Vitro Diagnostics Company
AQ
05/18NORGES BANK  : - Form 8.3 - Immunodiagnostic Systems Holdings Plc
PR
05/17IMMUNODIAGNOSTIC  : Agrees To $155 Million Takeover Bid From PerkinElmer
MT
05/17PERKINELMER  : to Acquire UK-Based Diagnostic Company Immunodiagnostic Systems
MT
More news
Financials
Sales 2020 39,3 M 54,3 M 54,3 M
Net income 2020 3,35 M 4,62 M 4,62 M
Net cash 2020 24,0 M 33,2 M 33,2 M
P/E ratio 2020 17,7x
Yield 2020 0,93%
Capitalization 109 M 150 M 150 M
EV / Sales 2019 0,62x
EV / Sales 2020 0,89x
Nbr of Employees 276
Free-Float 60,6%
Chart IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC
Duration : Period :
Immunodiagnostic Systems Holdings PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Jaap Stuut Chief Executive Officer & Director
Paul James Martin Finance Director, Secretary & Director
Burkhard Wittek Non-Executive Chairman
Peter John Williamson Independent Non-Executive Director
Peter Kaspar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC80.00%150
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.75.72%23 795
10X GENOMICS, INC.37.31%21 348
BIOMÉRIEUX S.A.-20.24%12 891
DIASORIN S.P.A.-9.52%9 981
NATERA, INC.3.38%9 015